Veronika Bachanova

Veronika Bachanova, MD, PhD serves as Professor and Section Head of Malignant Hematology within the Division of Hematology, Oncology, and Transplantation at the University of Minnesota Medical School. Her leadership focuses on advancing cellular therapies for hematologic malignancies through clinical research and patient care.

Her research centers on cutting-edge immunotherapies, particularly CAR-T cell therapy and natural killer cell therapies for B-cell malignancies. Current investigations include optimizing off-the-shelf iPSC-derived cellular products, managing treatment toxicities like cytokine release syndrome, and expanding applications to autoimmune disorders. Her work bridges translational research with real-world clinical implementation.

Analysis of her recent publications reveals a strong emphasis on CAR-NK cell technology, long-term outcomes of cellular therapies, and novel approaches to lymphoma treatment. Key trends include engineering persistence without conditioning chemotherapy, expanding therapeutic applications beyond oncology, and refining patient selection criteria through real-world data analysis.

Dr. Bachanova actively contributes to clinical practice guidelines through collaborations with major consortia including CIBMTR. Her leadership extends to educational initiatives focused on standardizing CAR-T therapy implementation and developing outpatient administration models.

Her clinical practice involves directing malignant hematology services with specialization in complex lymphoma cases and cellular therapy management. Current work prioritizes improving safety profiles of immunotherapies and addressing healthcare disparities in access to advanced treatments.